Hijacking client instability to selectively disrupt HSP90-driven glucocorticoid receptor activation [0.03%]
Elisa Longhi,Andrea Magni,Luca Torielli et al.
Elisa Longhi et al.
The molecular chaperone HSP90 drives the folding and activation of a broad spectrum of client proteins through dynamic, transient multiprotein assemblies. Although HSP90 has been widely pursued as an anticancer target, ATP-competitive inhib...
Honggang Ying,Lingxiang Ran,Yixuan Huang et al.
Honggang Ying et al.
Programmed cell death ligand 1 (PD-L1) serves as a major immune checkpoint, and immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have significantly advanced the landscape of tumor immunotherapy. However, current therapies t...
Phosphoproteomics identifies Rho-kinase-associated phospho-signaling and autophagy-associated alterations in the medial prefrontal cortex of a schizophrenia-related mouse model [0.03%]
Wenjun Zhu,Rinako Tanaka,Tetsuo Matsuzaki et al.
Wenjun Zhu et al.
Schizophrenia is a chronic, debilitating psychiatric disorder with high heritability. We have previously established Arhgap10 S490P/NHEJ (Arhgap10) mice, a schizophrenia-related mouse model carrying Japanese schizophrenia patient-derived AR...
Trends in drug discovery for carbonic anhydrases: FDA approvals, clinical trials, molecular functions, and therapeutic potential [0.03%]
Tautvydas Kojis,Helgi B Schiöth,Lina Baranauskiene et al.
Tautvydas Kojis et al.
Human carbonic anhydrases (CAs) catalyse the rapid conversion of CO₂ and bicarbonate, supporting pH balance, ion transport and many metabolic processes. All 15 human CA family proteins share a conserved structure, but they differ in activi...
Corrigendum to "The role of cannabinoid ligands in neurodegenerative diseases: Emerging anti-inflammatory, immunomodulation and disease-modifying perspectives" [Pharmacol. Res. 227 (2026) 108185] [0.03%]
Gabriela Mantovani Baldasso,Rodrigo Sebben Paes,Artur Graeff Moreira et al.
Gabriela Mantovani Baldasso et al.
Published Erratum
Pharmacological research. 2026 May:227:108206. DOI:10.1016/j.phrs.2026.108206 2026
Huichang Bi
Huichang Bi
Targeting mitochondrial quality control in Alzheimer's disease: Mechanisms and therapeutic potential of phytomedicines [0.03%]
Zhongying Lin,Shun Zhang,Miao Sun
Zhongying Lin
Alzheimer's disease (AD) is a neurodegenerative disorder driven partly by mitochondrial dysfunction, notably the failure of mitochondrial quality control (MQC). Phytochemicals have emerged as multi-target agents capable of restoring MQC, of...
Dual modulation of lipophagy: From molecular mechanisms to therapeutic interventions in cardiovascular health and disease [0.03%]
Yunxia Wu,Weili Li,Heng Liu et al.
Yunxia Wu et al.
The rising global incidence of cardiovascular diseases (CVDs) poses a serious challenge to public health systems, and there is an urgent need to alleviate this disease burden through innovative treatment strategies. Cardiomyocyte energy met...
AXL prevents amyloid-β-induced microglial ferroptosis by sustaining SLC2A3-mediated mitochondrial respiration [0.03%]
Shuai Liu,Chunjie Yang,Ningjun Zhang et al.
Shuai Liu et al.
Dysregulated iron metabolism is a pivotal driver of Alzheimer's disease (AD). Excess iron promotes Aβ aggregation and tau hyperphosphorylation, thereby accelerating disease progression. Serving as the primary iron reservoir in the central ...
Reconstitution of gut microbiota by medicinal plant isoflavones ameliorates heart failure with preserved ejection fraction [0.03%]
Jinghan Lin,Qianhui Zhu,Tao Wang et al.
Jinghan Lin et al.
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome with limited therapeutic options. Gut microbiota and microbiota-derived metabolites impact the progression and severity of HFpEF-related cardiometabolic dysf...